Brooks Sarah G, Yosipovitch Gil
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Clin Dermatol. 2025 Mar 17. doi: 10.1016/j.clindermatol.2025.03.013.
Prurigo nodularis (PN) is a chronic inflammatory dermatologic condition that is often incredibly itchy and imposes a debilitating burden on patient quality of life. Patients have historically faced the hurdles of limited knowledge regarding the mechanisms underlying PN, physician awareness, and effective therapies. Many of the conventional treatments offer minimal benefit or are accompanied by adverse effects. Over the last several years, striking advancements in the understanding of the pathogenesis contributing to PN have allowed for the development of novel treatments. The first and only medication approved by the US Food and Drug Administration is dupilumab, a biological agent targeting interleukins 4 and 13, has revolutionized management for patients with moderate-to-severe PN. Several other drugs are on the horizon that have the potential to become widely available. This contribution aims to review the current and emerging therapies for PN and address the challenges that may hinder effective treatment.
